Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Centrica to take 15% stake in £38bn Sizewell project

(Sharecast News) - British Gas-owner Centrica has taken a 15% stake in nuclear power station Sizewell C, it was announced on Tuesday, one of a number of new private investors to inject funds into the £38bn project. Following what is understood to be months of negotiations, Centrica confirmed it would take the stake with committed construction funding of £1.3bn.

It will be the third-largest shareholder after the government, which remains the biggest investor with a 44.9% holding. Canadian pension fund La Caisse will be the biggest private investor, after agreeing to take a 20% stake.

French state power firm EDF holds 12.5%, while specialist fund Amber Infrastructure Group has struck a deal to own 7.6%, with an option to acquire a further 2.4% from the government.

It had been widely reported that Canadian investment manager Brookfield would take a significant position, but the government instead opted to sell a larger stake to combination of different investors.

The expansion of Sizewell C, on the Suffolk coast, was initially proposed by EDF and China General Nuclear Power Group (CGN).

However, the government stepped in to remove CGN in 2022, on concerns about Chinese influence in key UK infrastructure, kickstarting the search for new private equity investors.

The project has also been heavily criticised by environmental groups, which are concerned about the impact on the local area.

However, the government pledged £11.5bn of new state funding for Sizewell earlier this month, as part of its wider plans to boost economic growth and improve the country's energy supply.

In total, the project is expected to cost around £38bn, significantly higher than the £20bn estimated by EDF and the government in 2020.

Chris O'Shea, Centrica chief executive, said: "The UK needs more reliable, affordable zero carbon electricity, and Sizewell C will be critical to supporting the country's energy system for many decades to come.

"That's why I'm delighted to be announcing this milestone investment, which will see Centrica commit £1.3bn for a 15% equity stake, and deepens our long-standing involvement in the UK nuclear industry."

The investment is part of the blue chip's £4bn green-focused investment programme. It currently expects a gross investment of around £500m cumulatively to the end of 2028, and over £1bn on the same basis by the end of 2033.

Sizewell is forecast to contributed around £50m of EBITDA per annum to Centrica by the end of 2028, £150m immediately pre-operations and "significant" acceleration once the plant enters the operational phase.

Sizewell is being built under a regulated asset base (RAB) model, which allows investors to get paid during construction rather than have to wait until the project is finished. A commercial operations date has been pencilled in for the mid-to-late 2030s.

Chancellor Rachel Reeves said: "La Caisse, Centrica's and Amber's multi-billion pound investment is a powerful endorsement of the UK as the best place to do business and as a global hub for nuclear energy.

"This investment will create thousands of good quality jobs and boost the local economy."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.